title: The function of the adrenocortical axis in permanent middle cerebral artery occlusion: effect of glucocorticoids on the neurological outcome.
abstract: We characterized the effect of acute ischemic stroke on the activation of the hypothalamic-pituitary-adrenal (HPA) axis and evaluated the role of glucocorticoids (GC) in the clinical outcome following ischemic stroke. Male spontaneous hypertensive rats underwent permanent middle cerebral artery occlusion (PMCAO) and developed a cortical infarct. At 4h post-PMCAO or sham operation, serum levels of ACTH and corticosterone (CS) were elevated 5 and 4 fold respectively as compared to controls and then returned to basal levels at 24h post surgery. In these experimental groups we found also a significant depletion of median eminence (ME)-CRH(41). In adrenalectomized (Adx) rats that underwent PMCAO the degree of motor disability and infarct volume was similar to that of intact rats. Administration of dexamethasone (Dex) to Adx-PMCAO rats significantly improved the motor disability and decreased the infarct volume. However, in sham-Adx with PMCAO, Dex had no effect on these two parameters. In rats with PMCAO or sham-PMCAO, brain production of PGE(2) was significantly increased. This effect was further enhanced in Adx-PMCAO rats and significantly inhibited by Dex. In conclusion, activation of the HPA axis following PMCAO is due to stress induced by surgery. This activation is mediated by hypothalamic CRH(41). Absence of endogenous GC or administration of Dex in naïve rats does not alter motor and pathological parameters in the acute stage following PMCAO. In contrast, administration of Dex significantly improved the outcome following cerebral ischemia in Adx rats which may be due to increased glucocorticoid receptors. Brain production of PGE(2) does not play an important role in the pathophysiology of the acute phase of cerebral ischemia.
authors: Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Jerusalem, Israel.
authors: J
authors: J
authors: Weidenfeld
authors: R R
authors: RR
authors: Leker
authors: N
authors: N
authors: Gai
authors: A
authors: A
authors: Teichner
authors: D
authors: D
authors: Bener
authors: H
authors: H
authors: Ovadia
mesh_terms: D000302:Adrenal Cortex / Q000502:physiology*; D000315:Adrenalectomy; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002545:Brain Ischemia / Q000150:complications / Q000503:physiopathology*; D003345:Corticosterone / Q000097:blood; D003346:Corticotropin-Releasing Hormone / Q000378:metabolism; D003907:Dexamethasone / Q000627:therapeutic use; D015232:Dinoprostone / Q000378:metabolism; D005938:Glucocorticoids / Q000502:physiology* / Q000627:therapeutic use*; D007030:Hypothalamo-Hypophyseal System / Q000502:physiology; D007031:Hypothalamus / Q000378:metabolism; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D007794:Lameness, Animal / Q000209:etiology / Q000473:pathology; D008297:Male; D008473:Median Eminence / Q000502:physiology; D010446:Peptide Fragments / Q000378:metabolism; D051381:Rats; D011918:Rats, Inbred SHR; D011965:Receptors, Glucocorticoid / Q000187:drug effects / Q000502:physiology; D020521:Stroke / Q000209:etiology / Q000503:physiopathology*; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D010446:Peptide Fragments; D011965:Receptors, Glucocorticoid; D003907:Dexamethasone; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; C045089:corticotropin releasing hormone (9-41); D015232:Dinoprostone; D003345:Corticosterone